Serum Concentration of Wnt2 and Wnt4 in Patients With Acute Coronary Syndrome

Study Overview
=================
Brief Summary
-----------------
This study aims to find the change of serum wnt effectory moleculars and the association with Hs-CRP，cTnI and Prognosis in Patients with Acute Coronary Syndrome.

Detailed Description
-----------------
It has been reported that wnt effecory moleculars (wnt2, wnt4, wnt11,wnt10b, DKK1, DKK2) increased in myocardium at acute phase after myocardium infarction in animal experiment. These moleculars can be detected in serum or plasma from human subjects. However, there is few relevant studies about wnt2 and wnt4 concentration in patients with acute coronary syndrome. This study valuates the serum wnt2 and wnt4 concentration in patients with acute coronary syndrome. It will possibly enable to find the relationship between serum wnt2 or wnt4 concentration and Hs-CRP, cTnI and prognosis in patients with Acute Coronary Syndrome.

Official Title
-----------------
Change of Serum Wnt2 or Wnt4 and the Relationship With Hs-CRP，cTnI and Prognosis in Patients With Acute Coronary Syndrome

Conditions
-----------------
Acute Coronary Syndrome

Intervention / Treatment
-----------------
* Other: Circulating wnt 2 and wnt 4 concentration


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: .diagnosed as acute coronary syndrome, including STEMI and NST-ACS. with left ventricular ejection fraction（LVEF）>=45% written informed consents are obtained admitted within 24 hours after chest pain attacked Exclusion Criteria: • complicated with rheumatic heart disease, coronary arteritis, hypertrophic cardiomyopathy or dilated cardiomyopathy complicated with malignant tumor,the immune system diseases, blood system diseases, recently (within 2 weeks) taking glucocorticoid drugs, the use of immunosuppressive agents and cerebral infarction with acute or chronic infection, surgery or trauma in the last month secondary hypertension, severe liver dysfunction,severe renal insufficiency with abnormal thyroid function or allergy to iodine agent refusal to sign the informed consent

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| STEMI group<br>The study population consists of 150 patients with ST-elevated acute myocardial infarction (STEMI) who are admitted within 24 hours after chest pain attack. They will all undergo coronary angiography. The diagnosis is made according to American Heart Association (AHA, 2014 and 2015) guidelines. Patients who had autoimmune diseases, malignancies, chronic or acute infections, asthma, severe heart failure (NYHA class 3 and 4) and advanced liver or renal diseases are excluded. Blood (150 each group) is obtained into ethylenediaminetetraacetic acid（EDTA） tubes from all subjects via antecubital venepuncture to explore circulating wnt 2 and wnt 4 concentration by ELISA at 0 , 7days and 12 months after admission. | Other: Circulating wnt 2 and wnt 4 concentration<br>* Blood (150 each group) is obtained into ethylenediaminetetraacetic acid（EDTA） tubes from all subjects via antecubital venepuncture to explore circulating wnt 2 and wnt 4 concentration by ELISA. Continuous wnt2 and wnt4 concentration are measured in all patients with STEMI at 0 , 7days and 12 months after admission. Other patients with acute syndrome system are measured Wnt 2 and wnt4 only once within 24h after admission. Wnt2 and wnt4 concentration in Control group will be measured only once with 24h after admission.<br>|
| NST-ACS group<br>The study population consists of 150 patients with non-ST elevated acute myocardial infarction (NST-ACS) including unstable angina pectoris (UAP),who are admitted within 24 hours after chest pain attack. They will all undergo coronary angiography. The diagnosis is made according to American Heart Association (AHA, 2014 and 2015) guidelines. Patients who had autoimmune diseases, malignancies, chronic or acute infections, asthma, severe heart failure (NYHA class 3 and 4) and advanced liver or renal diseases are excluded.Blood (150 each group) is obtained into ethylenediaminetetraacetic acid（EDTA） tubes from all subjects via antecubital venepuncture to explore circulating wnt 2 and wnt 4 concentration by ELISA at 0 , 7days and 12 months after admission. | Other: Circulating wnt 2 and wnt 4 concentration<br>* Blood (150 each group) is obtained into ethylenediaminetetraacetic acid（EDTA） tubes from all subjects via antecubital venepuncture to explore circulating wnt 2 and wnt 4 concentration by ELISA. Continuous wnt2 and wnt4 concentration are measured in all patients with STEMI at 0 , 7days and 12 months after admission. Other patients with acute syndrome system are measured Wnt 2 and wnt4 only once within 24h after admission. Wnt2 and wnt4 concentration in Control group will be measured only once with 24h after admission.<br>|
| Control group<br>150 age and body mass index matched healthy subjects with neither coronary artery disease nor any of the components of the metabolic syndrome are studied as Control group. Circulation wnt2 and wnt4 concentration in Control group will be measured only once with 24h after admission. | Other: Circulating wnt 2 and wnt 4 concentration<br>* Blood (150 each group) is obtained into ethylenediaminetetraacetic acid（EDTA） tubes from all subjects via antecubital venepuncture to explore circulating wnt 2 and wnt 4 concentration by ELISA. Continuous wnt2 and wnt4 concentration are measured in all patients with STEMI at 0 , 7days and 12 months after admission. Other patients with acute syndrome system are measured Wnt 2 and wnt4 only once within 24h after admission. Wnt2 and wnt4 concentration in Control group will be measured only once with 24h after admission.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Serum wnt2 and wnt4 concentration | Serum wnt2 and wnt4 concentration in ng/ml | 12 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Relationship between wnt2 or wnt4 and high sensitive C reaction protein (hs-CRP) concentration | Correlation of wnt2 and wnt4 with hs-CRP concentration | 12 months | 
| Relationship between wnt2 or wnt4 and Troponin-I (Tn-I) concentration | Correlation of wnt2 and wnt4 with Tn-I concentration | 12 months | 
| MACEs during 12-month follow-up | Association of wnt2 or wnt4 concentration with prognosis | 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Wnt signaling